Trial
NCT02053350
Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Virginia
Collaborators
—
Condition
Clostridium Difficile Infection
Intervention
Alanyl-glutamine
Why stopped
Funding ended
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-06-07